Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01889 (ankylosing spondylitis)
 5,717 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Advantages and disadvantages of trochanteric osteotomy were discussed. 716 total hip arthroplasties were performed in 594 patients. Trochanteric osteotomy was done in 79 hips (11%) of 68 patients: 39 cases of rheumatoid arthritis, 17 cases of ankylosing spondylitis, 9 cases of osteoarthritis and 3 cases of various conditions. In 73 hips the trochanter was reattached by Charnley, Coventry or Amstutz method; in remaining cases an original method was used. 42 hips in 36 patients were followed up. The results were evaluated on the basis of clinical, radiographic assessment and opinion of the patient. Trochanteric non-union was found in 3 hips (7.1%), delayed union in 2 cases (4.7%), the wire loop was broken in 6 hips (14.2%) with no disturbance of trochanteric union. The authors recommend Trochanteric osteotomy only in cases of difficult access to the joint or in order to prevent soft tissue damage in instances of difficult anatomic conditions.
Chir Narzadow Ruchu Ortop Pol 1990
PMID:[Should trochanteric osteotomy be performed during total hip replacement?]. 136 47

One-hundred patients with cervical vertebral changes, 100 with lumbar vertebral changes and 20 with ankylosing spondylitis were studied carrying out examinations of the sensation of touch, pain and vibration in these dermatomes and sclerotomes which are related to the levels of the most frequently occurring intervertebral disc changes. It was found that disturbances of the vibration sensation occurred significantly more frequently than disturbances of surface sensitivity, and their character suggested that they were a more specific sign of damage to the innervation of the spine than segmental disturbances of superficial sensitivity which are due to root damage.
Neurol Neurochir Pol
PMID:[Value of testing vibration sensation in diagnosing spondylogenic pain syndromes]. 360 Sep 73

Magnetic resonance (MR) imaging results in 8 from 14 ankylosing spondylitis patients treated of traumatic cervical spine and spinal cord injuries are presented. Focal changes within spinal cord were most common among complications (62%), epidural hematoma was found in 50% of cases. Neurological status has worsened in patients with post-traumatic spinal cord pathology.
Chir Narzadow Ruchu Ortop Pol 1995
PMID:[Injuries of the cervical spine and spinal cord in patients with ankylosing spondylitis--diagnosis using magnetic resonance imaging]. 856 77

Immunoglobulin A-alpha-1-antitrypsin complex (IgA-AT) is a nonimmune complex formed by disulphide bonding between an active thiol group available on the cysteine residue of alpha heavy chains of IgA and a cysteine in position 232 of alpha l-antitrypsin in single polypeptide chain. The level of the complex can easy be determined using the ELISA method and findings are expressed in arbitrary units. In the healthy adults' sera the IgA-AT complex level is lower than 0.4 arbitrary unit. The elevated levels of the complex were found in a number of rheumatic diseases. In 50% of SLE patients, its levels are increased, particularly in those with current central nervous system involvement. Similarly, in approximately 50% sera derived from RA patients they are also found to be higher. Their presence correlates with anatomical progression of the disease. IGA-AT complex is found in RA (in 90% of cases) but not in the osteoarthritis synovial fluid. Our findings can be applied in clinical praxis in differential diagnosis of early rheumatoid arthritis and osteoarthritis. The IGA-AT complex can be also found in ankylosing spondylitis. The complex has been determined in a relatively large number of IgA myeloma sera. In 30% of the cases its levels were 10-fold higher than the upper limit for healthy adults.
Mater Med Pol
PMID:Immunoglobulin A--alpha-1-antitrypsin complex in rheumatic diseases. 930 36

Early and late results of surgical treatment for Dupuytren contracture within 53 hands in 47 patients aged 19-72 (mean 58) are presented. Early results depended on magnitude of deformity and late ones (3-7 years after surgery) depended on recurrence of the contracture. In patients who had rheumatoid arthritis or the results were slightly worse; pathological changes within the hand were to blame and not the recurrence of contracture itself. No difference in histopathology of this condition was observed between rheumatoid arthritis-group- and ankylosing spondylitis patients.
Chir Narzadow Ruchu Ortop Pol 1997
PMID:[Results of surgical treatment for Dupuytren contracture]. 949 Feb 50

61 years old man with 30-years history of ankylosing spondylitis was admitted to hospital because of respiratory and cardiac failure. Chest X-ray and CT scan showed nonspecific inflammation but microbiological diagnosis allowed to establish the diagnosis of pulmonary tuberculosis. During antibioticotherapy and antituberculous treatment respiratory failure regressed.
Pneumonol Alergol Pol 2001
PMID:[Pulmonary tuberculosis during a course of ankylosing spondylitis]. 1157 4

The spondyloarthropathies (SpA) are a heterogenous group of diseases associated with axial and peripheral arthritis, enthesitis, inflammatory bowel disorders, presence of HLA B27 antigen and often with iridocyclitis. The aim of our study was to assess the efficacy of infliximab (chimeric monoclonal IgG 1 anti-TNF-alpha antibody) in the treatment of three patients with SpA. In two male patients (45- and 50-year old) psoriatic arthritis was diagnosed 28 and 22 years ago, and in 22-year old man ankylosing spondylitis was found before eight years. In all three cases dramatic response, almost complete resolution of joint manifestations and in patients with psoriatic arthritis regression of skin eruptions typical for psoriasis after one or two infusions was observed. In our opinion, the most optimal schedule of infliximab infusions was administration of the drug at weeks 0, 2, 6 and then every six weeks for at least 12 months. Discontinuation of therapy is associated with recurrence of symptoms of joint inflammation and increase in skin eruptions in patients with psoriatic arthritis within a few months.
Pol Arch Med Wewn 2005 Jan
PMID:[Treatment outcome of spondyloarthropathy with infliximab]. 1613 Jun

Systemic inflammatory disorders like rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are characterized by extensive dysregulation of bone metabolism recognized as focal articular bone erosions, juxta-articular and systemic bone loss. The complex interactions between bone cells, osteoprotegerin/RANKL pathway and a variety of inflammatory mediators are involved in the pathogenesis of focal and systemic osteopenia. Treatments with TNF-alpha blockers inhibit inflammation-induced bone resorption and might prevent structural bone damage in RA. In some studies with anti-TNF agents, an increase in BMD has been documented in spondyloarthropathies and in RA. The B-cell depleting antibody rituximab and the T-cell costimulation blocker abatacept are emerging as other effective treatment options in RA. Studies with anti- RANKL antibody Denosumab in RA demonstrate, that treatment targeting RANKL prevents development of erosions but not inflammation. This article reviews recent scientific literature regarding the effects of modern targeted therapies on bone turnover, bone mass and focal damage of joints.
Endokrynol Pol
PMID:[Effects of biologic antirheumatic treatments on bone metabolism in rheumatoid arthritis and ankylosing spondylitis]. 1939 55

Spondyloarthropathies belong to a group of rheumatic diseases, in which inflammatory changes affect mainly the sacroiliac joints, spine, peripheral joints, tendon, ligaments and capsule attachments (entheses). This group includes 6 entities: ankylosing spondylitis, arthritis associated with inflammatory bowel disease, reactive arthritis, undifferentiated spondyloarthropathy, psoriatic arthritis and juvenile spondyloarthropathy. In 2009, ASAS (Assessment in SpondyloArthritis international Society) association, published classification criteria for spondyloarthropathies, which propose standardization of clinical-diagnostic approach in the case of sacroiliitis, spondylitis and arthritis. Radiological diagnosis of inflammatory changes of sacroiliac joints is based on a 4 step radiographic grading method from 1966. According to modified New York criteria, the diagnosis of ankylosing spondylitis is made based on the presence of advanced lesions, sacroiliitis of at least 2 grade bilaterally or 3-4 unilaterally. In case of other types of spondyloarthropathies diagnosis is made based on presence of at least grade 1 changes. In MRI, active inflammation of sacroiliac joints is indicated by the presence of subchondral bone marrow edema, synovitis, bursitis, or enthesitis. ASAS discusses only the classic form of axial spondyloarthropathies, which is ankylosing spondylitis. To quantify radiological inflammatory changes in the course of the disease, Stoke Ankylosing spondylitis classification Spinal Score (SASSS) is recommended. The signs of inflammation and scarrying of the spinal cord in the course of ankylosing spondylitis, present in MRI include: bone marrow edema, sclerosis, fat metaplasia, formation of syndesmophytes, and ankylosis.
Pol J Radiol 2013 Apr
PMID:Diagnostic imaging of sacroiliac joints and the spine in the course of spondyloarthropathies. 2380 84

Therapy of chronic rheumatic diseases, such as rheumatoid arthritis (RA) and ankylosing spondylitis (AS) needs a comprehensive approach to the patient, based on the control of pain and improvement in overall condition, which affects the quality-of-life. This requires optimizing the treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or analgesics and control of adverse drug reactions. The aim of the study was to evaluate the efficacy and safety of pain pharmacotherapy in patients with rheumatoid arthritis and ankylosing spondylitis treated as the basic pharmacotherapy-biological drugs, the analysis of awareness of pharmacovigilance and evaluation of analgesic treatment costs. Material and methods. Examined group consisted of 102 people with RA or AS received biological therapy. Test method was questionnaire with closed and open questions. Results. 86.2% of respondents used a pain medication (41%--an ad hoc basis, but 23%--at least once a day), while 79.4%--NSAIDs (33%--an ad hoc basis and 17%--at least once a day). In 85.3% of those not observed adverse effects of pain pharmacotherapy. 5 persons declared abdominal pain. Most of the patients complied with the recommendations of the doctor in the pain treatment. For the third respondents the cost of pharmacotherapy of pain was monthly 1-10 zl, but 6% of patients paying for drugs from 50-60 and above 60 zl monthly. Conclusions. Biological treatment in RA and AS is effective but requires additional analgesic therapy. Adverse effects seen during pharmacological treatment of chronic pain in rheumatic diseases are, in practice sporadic. Therapeutic patient education with chronic diseases is proper. Costs borne by the patient's pain relief in this group are not too high.
Pol Merkur Lekarski 2014 Nov
PMID:[Welfare as the goal of the analgesic pharmacotherapy accompanying biological treatment in patients with rheumatoid arthritis and ankylosing spondylitis]. 2554 88


1 2 Next >>